Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
CMT4 Research
…IND submission process. Project Updated: February 18, 2025 CMTA-STAR Accelerates Progress Toward Transformative Treatments for CMT4C Through these ambitious efforts, CMTA-STAR is driving groundbreaking progress toward effective treatments for CMT4C…
Vera Fridman, MD joins the CMTA STAR Advisory Board
…on paving the way for, and executing, treatment trials for neuropathy. Dr. Fridman’s research aims to address the barriers to effective clinical trials in Charcot-Marie-Tooth (CMT) disease through the execution…
Gene Therapy Advances for CMT4J, CMT4A and GAN
…a gene therapy for one rare form of CMT called Giant Axonal Neuropathy, and aims to develop similar gene therapy treatments for other forms of CMT. Dr. Gray is a…
CMTA Lunch & Learn: Neuro-Toxic Medication List Update
07/13/2023 @ 12:00 pm – 1:00 pm – Please join us on July 13 at 12:00 p.m. Eastern Time to hear an update on the newly reviewed and revised CMT Neuro-toxic Medication List. The CMTA funded a grant awarded to Guido Cavaletti, MD at the University of Milano-Bicocca to review and update the current CMT neuro-toxic medication list. Dr. Cavaletti and colleague, Dr. […]
CMTA Updates List of Neurotoxic Meds Potentially More Hazardous to CMT Patients
…than for people who do not have CMT. The reviewers emphasized the importance of not denying patients with CMT treatments that may prolong life expectancy for cancer or improve their…
CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT
…global leadership in advancing treatments for CMT and it underscores the association’s commitment to improving the lives of those who have CMT, while strengthening its dedication to developing treatments and,…
The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
…Laura Feltri will be deeply missed.” Dr. Feltri was a dedicated supporter of our mission to support the development of new treatments for CMT, to improve the quality of life…
CMT2S Breakthrough
…marks a significant step forward for community members who have CMT2S. CMT2S is a very rare and often debilitating autosomal recessive type of CMT. A potential treatment for CMT2S, Vanda’s…
Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
…tolerability, and efficacy (how well the treatment works) of NMD670 over 21 days in 80 adult patients with genetically confirmed CMT types 1 and 2. Shared Vision for Progress “This…
SORD Research
…some of the advances in the eventual treatment of axon degeneration may be applicable as these therapies are developed. If your type is not yet identified, please visit a CMTA…